


Catalog# BP-50205

Polatuzumab vedotin

Description:

Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate (ADC) consisting of three components: 1) the humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b; 2) the small molecule anti-mitotic agent MMAE; and 3) a protease-cleavable linker maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to the polatuzumab antibody. It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Polatuzumab vedotin-piiq has an approximate molecular weight of 150 kDa. An average of 3.5 molecules of MMAE are attached to each antibody molecule. This product is for research use only. Polatuzumab vedotin-piiq has the following structure:



Product Details	
CAS No.	1313206-42-6
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Polatuzumab (Anti-CD79b)
Target	Humam CD79b
ADC cytotoxin (drug)	MMAE
Purity	99%
DAR	~3.5
Molecular Weight	150kDa
Formulation	100 mM Pro-Ac, 20 mM Arg, pH 5.0
Purification	Size exclusive column
Storage conditions	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.